Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Epitalon vs Cartalax

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Epitalon has stronger documented evidence (Russia-Clinical + Animal Studies) than Cartalax (Russian Research) while both occupy the khavinson class. When clinical-evidence tier is the deciding factor, Epitalon is the safer pick. Cartalax may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Epitalon

Russia-Clinical + Animal Studies

Cartalax

Russian Research

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

Epitalon Cartalax
Class Khavinson pineal tetrapeptide; longevity peptide Khavinson short peptide bioregulator
Drug class Longevity Longevity
Mechanism Activates telomerase gene expression; modulates pineal function and melatonin secretion Tissue-specific gene expression modulation in chondrocytes
Route SC / Oral Oral
Half-life ~20 min Short (minutes)
Dosage (research) 5 mg SC daily for 10-20 day cycles 2x yearly (Khavinson Russian gerontology starting dose, range up to 10 mg/day per published protocols) Oral capsule 1-2x daily
Evidence tier Russia-Clinical + Animal Studies Russian Research
Research depth 155 indexed (PubMed 143 · CT 1 · EPMC 11) 2 indexed (PubMed 0 · CT 0 · EPMC 2)
Availability Research Research
Reported risks Limited Western trials; Russian-origin data Limited Western evidence

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Epitalon or Cartalax?

Epitalon has stronger documented evidence (Russia-Clinical + Animal Studies) than Cartalax (Russian Research) while both occupy the khavinson class. When clinical-evidence tier is the deciding factor, Epitalon is the safer pick. Cartalax may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between Epitalon and Cartalax?

Epitalon is classed as Khavinson pineal tetrapeptide; longevity peptide; Cartalax is classed as Khavinson short peptide bioregulator. Reported mechanism: Epitalon, Activates telomerase gene expression; modulates pineal function and melatonin secretion; Cartalax, Tissue-specific gene expression modulation in chondrocytes. Reported half-life: Epitalon, ~20 min; Cartalax, Short (minutes). Routes in published studies: Epitalon, SC / Oral; Cartalax, Oral.

Which has stronger evidence, Epitalon or Cartalax?

Epitalon has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Epitalon is graded Russia-Clinical + Animal Studies, with 7 cited sources on its reference page and 155 indexed studies. Cartalax is graded Russian Research, with 2 cited sources on its reference page and 2 indexed studies.

Which is more accessible, Epitalon or Cartalax?

Neither Epitalon nor Cartalax is an FDA-approved drug. Catalog status: Epitalon, Research; Cartalax, Research. Epitalon's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.

Are Epitalon and Cartalax ever combined?

Epitalon and Cartalax appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…